Physician profile
Christopher Brian Perry
NPI 1457353104
$10,780.71
in general payments reported to CMS, 2019-2025
28 companies · $2,614 in 2025
The $2,614 reported for 2025 was more than what 92% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,025 · 2020: $897 · 2021: $1,532 · 2022: $2,016 · 2023: $1,320 · 2024: $1,378 · 2025: $2,614.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,223 · Education: $88.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,222.57 |
| Education | $88.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $1,572.43 | 2019-2025 | |
| Genzyme Corporation | $1,361.89 | 2019-2025 | |
| Abbvie INC. | $1,216.80 | 2022-2025 | |
| Acclarent, INC | $1,159.98 | 2019-2023 | Relieva Spinplus |
| Glaxosmithkline, LLC. | $891.42 | 2021-2025 | Nucala |
| Aerin Medical INC. | $831.94 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $660.12 | 2019-2025 | Dupixent |
| Pfizer INC. | $470.77 | 2023-2025 | |
| Intersect Ent, INC. | $408.10 | 2019-2022 | |
| Medtronic, INC. | $216.59 | 2021-2025 | Propel |
| Biohaven Pharmaceuticals, INC. | $214.27 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $196.10 | 2021-2024 | |
| Phathom Pharmaceuticals, INC. | $195.91 | 2024-2025 | Voquezna |
| Amgen INC. | $182.73 | 2021-2025 | Tezspire |
| Sanofi-Aventis U.S. LLC | $177.95 | 2020-2023 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $170.30 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $153.19 | 2022 | |
| Stryker Corporation | $135.69 | 2019-2021 | |
| Axsome Therapeutics, INC. | $124.56 | 2025 | Symbravo |
| Cochlear Americas | $109.22 | 2025 | Cochlear Nucleus Ci632 Cochlear Implant With Slim Modiolar Electrode, Baha, Osia Osi300 Implant |
| Smith+Nephew, INC. | $80.69 | 2019-2022 | |
| Alk-Abello, INC | $70.65 | 2021-2023 | Timothy, Standardized, Standardized Mite D. Farinae, Pre-Pen |
| Phadia US INC. | $52.19 | 2021-2024 | Immunocap |
| Pacira Pharmaceuticals Incorporated | $37.64 | 2019-2025 | Exparel |
| Fortovia Therapeutics, INC. | $36.32 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $25.25 | 2022-2023 | Seglentis |
| Integra Lifesciences Corporation | $15.08 | 2025 | Inspira Air, Acclarent Aera, Trudi Probe |
| Lilly USA, LLC | $12.93 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Perry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.